ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile dermatomyositis and rituximab"

  • Abstract Number: 17 • 2018 ACR/ARHP Annual Meeting

    Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab

    Amer khojah1,2, Victoria Hans3, Wilfredo Marin4, Gabrielle A. Morgan4 and Lauren M. Pachman5,6,7, 1Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Division of Pediatric Allergy Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 3Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 6Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 7Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL

    Background/Purpose: Rituximab is used for the treatment of juvenile dermatomyositis (JDM) with variable success. Some of this variability is presumed to be related to the…
  • Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results

    Anjali Patwardhan1, Kelly A. Rouster-Stevens2, Harry L. Gewanter3, Grant D. Syverson4, Renee F. Modica5, Kara M. Schmidt6 and Charles H. Spencer7, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, 3Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, 4Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 5Pediatric Rheumatology, University of Florida, Gainesville, FL, 6Pediatric Rheumatology, Univ of Louisville, Louisville, KY, 7Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders.  Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology